Overview

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Status:
Active, not recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Dasatinib